Yahoo Finance Earnings Update: BioNTech SE (NASDAQ:BNTX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
A week ago, BioNTech SE (NASDAQ:BNTX) came out with a strong set of first-quarter numbers that could potentially lead to a re-rate of the stock. The overall earnings picture was okay, with revenues of €28m beating expectations by 14%. Statutory losses were €0.24 per share, only marginally better than what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Check out our latest analysis for BioNTech
After the latest results, the seven analysts covering BioNTech are now predicting revenues of €128.1m in 2020. If met, this would reflect a solid 16% improvement in sales compared to the last 12 months. Losses are forecast to balloon 20% to €1.02 per share. Before this earnings announcement, the analysts had been modelling revenues of €129.8m and losses of €1.10 per share in 2020. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
The average price target held steady at €38.95, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic BioNTech analyst has a price target of €55.41 per share, while the most pessimistic values it at €18.97. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing stands out from these estimates, which is that BioNTech is forecast to grow faster in the future than it has in the past, with revenues expected to grow 16%. If achieved, this would be a much better result than the 17% annual decline over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 24% per year. So although BioNTech's revenue growth is expected to improve, it is still expected to grow slower than the industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting sales are tracking in line with expectations - although our data does suggest that BioNTech's revenues are expected to perform worse than the wider industry. The consensus price target held steady at €38.95, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple BioNTech analysts - going out to 2024, and you can see them free on our platform here.
And what about risks? Every company has them, and we've spotted 2 warning signs for BioNTech you should know about.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
